期刊文献+

反义寡核苷酸抑制survivin表达来增强乳腺癌细胞株MCF-7和MDA-MB-231对多西他赛敏感性的研究 被引量:1

Antisense oligonucleotide inhibits sensitivity of human breast cancer cells MCF-7 and MDA-MB-231 to docetaxel
下载PDF
导出
摘要 目的:探讨利用反义寡核甘酸(ASODN)技术封闭乳腺癌细胞株survivin基因,观察survivin基因表达下调能否诱导细胞凋亡及增强对多西他赛(docetaxel)药物敏感性。方法:Survivin ASODN单独及联合多西他赛处理乳腺癌细胞株MCF-7和MDA-MB-231,RT-PCR检测survivin mRNA的表达,免疫细胞化学方法和W estern b lotting检测survivin蛋白表达,倒置显微镜观察细胞形态变化,MTT法检测细胞的生长抑制率。结果:Survivin ASODN可下调人乳腺癌细胞株中survivin mRNA和蛋白质的表达;survivin ASODN与多西他赛联合用药组相比对照组和多西他赛组可明显抑制细胞株的生长(P<0.01)。结论:Survivin ASODN明显抑制survivin基因在乳腺癌细胞株MCF-7和MDA-MB-231中的转录及翻译,明显提高乳腺癌对多西他赛的敏感性。 Objective Through interfering the expression of survivin with survivin ASODN,to of downregulation of survivin on cell apoptosis and chemosensitivity to docetaxel in breast cancer c investigate the effect ells. Methods The one or together. The n was tested with immunocytochemistry and Western blotting analysis. Cell morphological transformation was observed with inverted microscope. The inhibitive rates of the ceils was determined by MTT. Results Survivin ASODN could down-regulate the expression of survivin. The growth of breast cancer cells can be significantly inhibited by combined survivin ASODN and docetaxel group. The effect was higher than that of control and docetaxel group ( P〈0.01 ). Conclusion These results show that by survivin ASODN, survivin expression can be effectively decreased at both transcriptional and translational level. The reduction of survivin expression exerts significant effects on chemosensitivity of breast cancer cells MCF-7 and MDA-MB-231 to docetaxel.
作者 张静 姜藻
出处 《东南大学学报(医学版)》 CAS 2009年第1期6-10,共5页 Journal of Southeast University(Medical Science Edition)
基金 安徽省自然科学基金资助项目(070413119) 蚌埠市科技计划项目(200843)
关键词 生存素 反义寡核苷酸 多西他赛 乳腺癌细胞株 survivin antisense oligonucleotide docetaxel breast cancer cells
  • 相关文献

参考文献3

二级参考文献33

  • 1[1]Andersson M,Madsen EL,Overgaard M,et al.Doxorubicin versus methotrexate both combined with cyclophosphamide,5-fluorouracil and tamoxifen in postmenopausal patients with advanced breast cancer-a randomised study with more than 10 years follow-up from the Danish Breast Cancer Cooperative Group.Danish Breast Cancer Cooperative Group(DBCG)[J].Eur J Cancer,1999,35(1):39-46.
  • 2[2]Lyass O,Uziely B,Ben-Yosef R,et al.Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin(Doxil) in metastatic breast carcinoma[J].Cancer,2000,89(5):1037-1047.
  • 3[3]Valero V,Buzdar AU,Theriault RL,et al.Phase Ⅱ trial of liposome-encapsulated doxorubicin,cyclophosphamide,and fluorouracil as first-line therapy in patients with metastatic breast cancer[J].J Clin Oncol,1999,17(5):1425-1434.
  • 4[4]Estaban E,Lacave AJ,Fernandez JL,et al.Phase Ⅲ trial of cyclophosphamide,epirubicin,fluorouracil(CEF) versus cyclophosphamide,mitoxantrone,fluorouracil(CNF) in women with metastatic breast cancer[J].Breast Cancer Res Treat,1999,58(2):141-150.
  • 5[5]Bishop JF,Dewar J,Toner GC,et al.Initial paclitaxel improves outcome compared with CMFP combination chemotherapy as front-line therapy in untreated metastatic breast cancer[J].J Clin Oncol,1999,17:2355-2364.
  • 6[6]Paridaens R,Biganzoli L,Bruning P,et al.Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer:a European Organization for Research and Treatment of Cancer Randomized Study with cross-over[J].J Clin Oncol,2000,18(4):724-733.
  • 7[7]Nabholtz JM,Senn HJ,Bezwoda WR,et al.Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy.304 Study Group[J].J Clin Oncol,1999,17(5):1413-1424.
  • 8[8]Sjostrom J,Blomqvist C,Mouridsen H,et al.Docetaxel compared with sequential methotrexate and 5-fluorouracil in patients with advanced breast cancer after anthracycline failure:a randomised phase Ⅲ study with crossover on progression by the Scandinavian Breast Group[J].Eur J Cancer,1999,35(8):1194-1201.
  • 9[9]Chan S,Friedrichs K,Noel D,et al.Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer.The 303 Study Group[J].J Clin Oncol,1999,17(8):2341-2354.
  • 10[10]Pluzanska A,Pienkowski T,Jelic S,et al.Phase multicenter trial comparing Toxol/doxorubicin(AT) vs 5-fulorouracil/doxorubicin and cyclophosphamide(FAC) as a first line treatment for patient with metastatic breast cancer[J].Breast cancer Res Treat,1999,57:21a.

共引文献64

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部